SWP
GNOM icon

ShoreHaven Wealth Partners’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

ShoreHaven Wealth Partners’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-306
Closed -$28K – 133
2021
Q1 		$28K Buy
+306
New +$30.2K 0.02% 147

Other funds holding GNOM

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $1.14B AUM 79.59% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

ShoreHaven Wealth Partners's GNOM Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q2 2021, closing a stake of 306 shares — an estimated $28K sold.

ShoreHaven Wealth Partners first reported a position in GNOM in Q1 2021 and held it in 1 quarter. The position peaked at $28K in Q1 2021. 46 funds tracked by Wall St. Rank hold GNOM as of Q2 2021.

  • ShoreHaven Wealth Partners reported no remaining Global X Genomics & Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
  • ShoreHaven Wealth Partners sold 306 Global X Genomics & Biotechnology ETF shares in Q2 2021, an estimated $28K.
  • ShoreHaven Wealth Partners first reported a position in Global X Genomics & Biotechnology ETF in Q1 2021 and held it in 1 quarter.
  • ShoreHaven Wealth Partners's Global X Genomics & Biotechnology ETF position peaked at $28K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.